Intelligence · Clinical Development
Pipeline search results
Programs matching “ipilimumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 12 pipeline programs matching "ipilimumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Ipilimumab
Bristol-Myers Squibb
Melanoma
1 trial -
UC-IMM-2101
Ningbo Cancer Hospital
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
IPILIMUMAB for metastasized melonama uveal
Disc Medicine
metastasized melonama uveal
1 trial -
IPILIMUMAB, NIVOLUMAB
Ningbo Cancer Hospital
type B3 thymoma and thymic carcinoma
1 trial -
Ipilimumab
United Therapeutics Europe Ltd
Locally Advanced Clear Cell Renal Cell Carcinoma
1 trial -
Ipilimumab
United Therapeutics Europe Ltd
BCLC Stage B Hepatocellular Carcinoma
1 trial -
Nivolumab & Ipilimumab
The First People's Hospital of Lianyungang
Lung Cancer - Non Small Cell
1 trial -
ZZ-IT-ICI-HCC 1line-023
Second Affiliated Hospital of Soochow University
Liver Cancer
1 trial -
nivolumab, ipilimumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatocellular Carcinoma (HCC)
1 trial -
Ipilimumab
Regeneron UK Limited
Stage III Prostate Cancer
1 trial -
Ipilimumab
VACCINEX, INC.
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
1 trial -
Ipilimumab
Iovance Biotherapeutics B.V.
Metastatic Melanoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.